Editas Medicine Stock Fundamentals
| EDIT Stock | USD 1.46 0.09 6.57% |
Editas Medicine fundamentals help investors to digest information that contributes to Editas Medicine's financial success or failures. It also enables traders to predict the movement of Editas Stock. The fundamental analysis module provides a way to measure Editas Medicine's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Editas Medicine stock.
At this time, Editas Medicine's Gross Profit is comparatively stable compared to the past year. Cost Of Revenue is likely to gain to about 214.5 M in 2025, whereas Selling General Administrative is likely to drop slightly above 59.8 M in 2025. Editas | Select Account or Indicator |
Editas Medicine Company Current Valuation Analysis
Editas Medicine's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Editas Medicine Current Valuation | (121.2 M) |
Most of Editas Medicine's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Editas Medicine is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Editas Current Valuation Historical Pattern
Today, most investors in Editas Medicine Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Editas Medicine's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Editas Medicine current valuation as a starting point in their analysis.
Editas Medicine Current Valuation |
| Timeline |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Editas Medicine has a Current Valuation of (121.2 Million). This is 100.84% lower than that of the Biotechnology sector and 102.61% lower than that of the Health Care industry. The current valuation for all United States stocks is 100.73% higher than that of the company.
Editas Medicine Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Editas Medicine's current stock value. Our valuation model uses many indicators to compare Editas Medicine value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Editas Medicine competition to find correlations between indicators driving Editas Medicine's intrinsic value. More Info.Editas Medicine is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Editas Medicine's Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Editas Medicine by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Editas Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Editas Medicine's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Editas Medicine could also be used in its relative valuation, which is a method of valuing Editas Medicine by comparing valuation metrics of similar companies.Editas Medicine is currently under evaluation in current valuation category among its peers.
Editas Medicine Current Valuation Drivers
We derive many important indicators used in calculating different scores of Editas Medicine from analyzing Editas Medicine's financial statements. These drivers represent accounts that assess Editas Medicine's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Editas Medicine's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 4.1B | 1.8B | 609.1M | 769.5M | 104.6M | 99.3M | |
| Enterprise Value | 4.0B | 1.6B | 511.5M | 682.4M | 8.1M | 7.7M |
Editas Fundamentals
| Return On Equity | -0.98 | ||||
| Return On Asset | -0.36 | ||||
| Operating Margin | (1.12) % | ||||
| Current Valuation | (121.2 M) | ||||
| Shares Outstanding | 82.98 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 66.10 % | ||||
| Number Of Shares Shorted | 17.44 M | ||||
| Price To Earning | (7.02) X | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 3.75 X | ||||
| Revenue | 32.31 M | ||||
| Gross Profit | (166.93 M) | ||||
| EBITDA | (233.11 M) | ||||
| Net Income | (237.09 M) | ||||
| Cash And Equivalents | 452.56 M | ||||
| Cash Per Share | 6.59 X | ||||
| Total Debt | 35.03 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 12.67 X | ||||
| Book Value Per Share | 1.62 X | ||||
| Cash Flow From Operations | (210.28 M) | ||||
| Short Ratio | 2.31 X | ||||
| Earnings Per Share | (2.88) X | ||||
| Target Price | 3.75 | ||||
| Number Of Employees | 246 | ||||
| Beta | 1.87 | ||||
| Market Capitalization | 121.15 M | ||||
| Total Asset | 341.59 M | ||||
| Retained Earnings | (1.47 B) | ||||
| Working Capital | 212.09 M | ||||
| Current Asset | 144.99 M | ||||
| Current Liabilities | 6.92 M | ||||
| Net Asset | 341.59 M |
About Editas Medicine Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Editas Medicine's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Editas Medicine using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Editas Medicine based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 6.2 M | 5.9 M | |
| Total Revenue | 32.3 M | 32 M | |
| Cost Of Revenue | 204.3 M | 214.5 M | |
| Stock Based Compensation To Revenue | 0.66 | 0.63 | |
| Sales General And Administrative To Revenue | 2.23 | 4.15 | |
| Research And Ddevelopement To Revenue | 2.62 | 2.48 | |
| Capex To Revenue | 0.27 | 0.33 | |
| Revenue Per Share | 0.39 | 0.42 | |
| Ebit Per Revenue | (7.77) | (8.16) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Editas Stock Analysis
When running Editas Medicine's price analysis, check to measure Editas Medicine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Editas Medicine is operating at the current time. Most of Editas Medicine's value examination focuses on studying past and present price action to predict the probability of Editas Medicine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Editas Medicine's price. Additionally, you may evaluate how the addition of Editas Medicine to your portfolios can decrease your overall portfolio volatility.